Benutzer: Gast  Login
Titel:

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.

Dokumenttyp:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Autor(en):
Ströhlein, MA; Lordick, F; Rüttinger, D; Grützner, KU; Schemanski, OC; Jäger, M; Lindhofer, H; Hennig, M; Jauch, KW; Peschel, C; Heiss, MM
Abstract:
Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC.In this open-label, phase I/II clinical trial, patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer received 4 sequential intraperitoneal catumaxomab infusions: day 0: 10 ?g; day 3: 10 or 20 ?g; day 7: 30, 50, or 100 ?g;...     »
Zeitschriftentitel:
Onkologie
Jahr:
2011
Band / Volume:
34
Heft / Issue:
3
Seitenangaben Beitrag:
101-8
Sprache:
eng
Volltext / DOI:
doi:10.1159/000324667
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/21358214
Print-ISSN:
0378-584X
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX